Longduoduo Co. Ltd. provides preventive healthcare solutions and services. The company is headquartered in Hohhot, Neimenggu and currently employs 49 full-time employees. The company went IPO on 2022-08-17. The firm provides solution for chronic disease problems through non-drug treatments and prevents cardiovascular and cerebrovascular diseases in advance. The firm offers health consultation and advice to customers and sells treatment services to customers, provided by Longduoduo to customers in local cooperative medical institutions. The firm's treatment projects mainly include ozone autologous blood transfusion (immunotherapy), Xingnao Tongluo therapy, double blood purification, platelet-rich plasma (PRP) injection therapy and others. The firm's products and services are mainly used for the prevention of myocardial infarction, cerebral infarction, hemiplegia, cardiovascular and cerebrovascular diseases. The firm mainly conduct its businesses in domestic market.
